Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma sets up $200 million at-the-market stock sale program with Jefferies

Neutral Impact 3 of 5 financing Written later

Nuvectis Pharma entered an agreement with Jefferies LLC on August 21, 2026, allowing it to sell up to $200 million of common stock through a new shelf registration. The company also ended its prior at-the-market program on July 20, 2026. Sales are not guaranteed, and shareholders could face dilution if shares are sold.

Key points

  • Open Market Sale Agreement with Jefferies LLC as sales agent, dated August 21, 2026
  • New Form S-3 shelf registration covering $200 million in securities, filed August 21, 2026
  • Jefferies fee of up to 3.0% of gross proceeds from ATM share sales
  • Prior at-the-market program terminated July 20, 2026; no further sales under it

The filing

CompanyNuvectis Pharma, Inc. (NVCT)
Form8-K, current report
Filed with the SECAug 21, 2026, 4:31 PM ET
Accession number0001104659-26-099712

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.